prismmarketview
Oct 12, 3:14 PM
Oct. 13 is National Metastatic Breast Cancer Awareness Day, which Congress recognized in 2009. It focuses on stage 4 disease, which has no cure. Per advocacy group METAvivor, 20-30% of early-stage breast cancers recur as stage 4, MBC accounts for 98% of breast cancer deaths, and less than 5% of research funding goes to metastatic disease. Emerging biotechs are working on the gap.
Names to watch:
BriaCell Therapeutics
$BCTX (Phase 3 Bria-ABC, interim readout expected this year)
Oncolytics Biotech
$ONCY (pelareorep, randomized Phase 2)
Enliven Therapeutics
$ELVN (ELVN-002 in HER2+ MBC, Phase 1)
Plus Therapeutics
$PSTV (REYOBIQ for leptomeningeal metastases)
Prelude Therapeutics
$PRLD (Phase 1 planned 2H 2026).
These are small-cap, clinical-stage companies with binary trial outcomes, thin liquidity, and likely future capital needs. Most programs are years from potential approval.
http://prismmarketview.com/closing-the-gap-emerging-biotechs-take-aim-at-metastatic-breast-cancer/
